How Journals and Sponsors Shape Open Access in Clinical Trial Publication

Introduction: Why Open Access is Now Non-Negotiable

Open access (OA) has moved from being an academic preference to a clinical trial mandate. Regulatory agencies, funding bodies, and public advocacy groups are demanding increased transparency and wider availability of trial data. At the center of this movement are journal publishers and study sponsors, whose open access policies shape how, when, and where clinical trial results are published and accessed.

This article dives into the policies enforced by top medical journals and sponsors, the legal and ethical mandates around data dissemination, and the strategic decisions pharma professionals must make to stay compliant with evolving expectations.

Types of Open Access Models Explained

Before exploring specific policies, it’s crucial to understand the main OA models that journals and sponsors support:

• Gold Open Access: Articles are immediately free upon publication. Often involves an Article Processing Charge (APC).
• Green Open Access: Authors self-archive a version (pre-print or post-print) in a public repository after an embargo period.
• Hybrid Access: Subscription journals offer optional open access for individual articles upon payment of APC.
• Bronze Access: Articles are free to read but lack a clear reuse license.

Most clinical trial sponsors favor Gold or Green models to ensure compliance with funder mandates and transparency guidelines.

Major Sponsor Requirements for Open Access

Pharmaceutical sponsors and public agencies have begun enforcing open access publication as a formal requirement. Below is a snapshot of leading mandates:

Open Access Mandates from Major Journals

Leading medical journals have differing OA policies that authors must navigate:

• The BMJ: Full Gold OA journal. Mandates CC-BY license for research articles.
• NEJM: Subscription-based with optional OA for selected articles (high APC).
• The Lancet: Hybrid model. OA allowed with Plan S-aligned license and payment.
• JAMA: Permits Green OA after embargo. Offers OA for funder-mandated papers.
• PLOS ONE: Gold OA journal. No subscription content. APC applies to all.

Authors publishing trial results must align journal selection with sponsor obligations and transparency goals.

Plan S and the Rise of Funder-Led Publishing Requirements

Plan S is a coalition of funders including the European Commission, Wellcome Trust, and others requiring that all research they fund be published in compliant OA journals or platforms. Requirements include:

• Immediate open access without embargo
• Use of Creative Commons Attribution License (CC BY)
• Deposition in approved repositories
• Transparency in APC pricing

For clinical trial teams working under these funders, failing to publish in a compliant venue may jeopardize future funding.

Case Example: NIH-Funded Oncology Trial

A multicenter oncology trial funded by the NIH completed in 2022. As per NIH’s Public Access Policy, the manuscript was submitted to a hybrid journal that did not offer immediate open access. The team faced the following challenges:

• Delayed deposit of the accepted manuscript in PubMed Central
• Need to revise the publishing agreement to enable Green OA
• Inclusion of proper grant acknowledgment and NIH grant number

Ultimately, compliance was achieved after coordination with the publisher and NIH Manuscript Submission system (NIHMS).

Embargo Periods: How Long Can Access Be Delayed?

Embargoes refer to the time between article publication and when it becomes freely accessible in a public repository. Funders and journals vary:

• NIH: 12 months maximum
• Wellcome: No embargo allowed
• EC Horizon: Immediate access required
• NEJM: 6 months common unless OA option selected

Trial sponsors must integrate embargo planning into their publication strategy to avoid non-compliance.

Journals vs Repositories: Parallel Dissemination Strategy

Most funders allow dual routes of dissemination:

1. Journal Publication: Peer-reviewed, formal publication
2. Repository Submission: Depositing accepted manuscript in platforms like PubMed Central, Europe PMC, or institutional repositories

For example, a trial published in JAMA may have its accepted version archived in Europe PMC under funder guidelines. Both routes contribute to visibility and access.

Publication SOPs for Sponsors

Pharma companies and CROs must maintain internal SOPs that align with global OA mandates. These SOPs often include:

• Pre-submission compliance checks
• Preferred journal list with OA compatibility
• Coordination with medical writers and authors
• Archiving requirements in corporate repositories
• Communication with funders on embargo negotiations

Failure to follow these SOPs can result in inspection findings under GPP3 (Good Publication Practice) guidelines.

Best Practices for Trial Teams

• Check funder OA mandates before selecting a journal
• Choose journals indexed in trial registries or connected to ORCID/iCite
• Budget for APCs in grant or sponsor funding plans
• Document all communications with publishers regarding access rights
• Use institutional OA advisors to resolve legal conflicts

Planning ahead minimizes the risk of non-compliance and improves the trial’s dissemination timeline.

Conclusion: Ensuring Access to Scientific Knowledge

Open access policies are no longer optional — they are legally and ethically mandated across the global clinical trial landscape. Journals and sponsors play pivotal roles in ensuring trial outcomes are not locked behind paywalls. By understanding the varying models, planning for APCs, and aligning with sponsor and funder expectations, clinical research teams can ensure that trial results reach the widest possible audience — fostering public trust, advancing science, and meeting transparency goals.

The AllTrials Campaign: Evolution, Impact, and Barriers

Introduction to the AllTrials Campaign

The AllTrials Campaign was launched in 2013 as a global movement to demand that all clinical trials—past and present—be registered and have their results reported. Initiated by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, the campaign quickly gained international traction and has since reshaped conversations around clinical transparency, ethics, and accountability in medical research.

The campaign’s motto, “All Trials Registered. All Results Reported.”, has become a rallying cry for researchers, regulatory bodies, journals, and patient advocacy groups. The underlying concern is simple yet urgent: missing clinical trial results distort the evidence base used by clinicians, regulators, and policymakers to make decisions about patient care.

Founding Organizations and Strategic Goals

The AllTrials campaign is driven by several well-respected organizations. Cochrane’s data-driven research approach, BMJ’s editorial stance, and the statistical scrutiny promoted by Goldacre’s initiatives have created a compelling synergy. The core objectives of the campaign include:

• Mandating public registration of all clinical trials at inception
• Ensuring timely disclosure of trial results, regardless of outcome
• Retrospective disclosure of older, unpublished trials
• Policy change at institutional, national, and international levels

Over time, the campaign has helped push forward policy reform and sponsor accountability. For example, many institutions now require ClinicalTrials.gov or EudraCT registration as a condition for IRB approval or journal publication.

Successes Achieved Through Advocacy and Policy Reform

Since its inception, AllTrials has garnered support from over 750 organizations worldwide, including universities, research sponsors, regulators, and patient groups. The campaign has led to tangible policy changes:

• The European Medicines Agency (EMA) launched a database to make clinical data publicly accessible.
• The U.S. Final Rule (FDAAA 801) clarified disclosure expectations and timelines.
• WHO’s Joint Statement echoed many of AllTrials’ demands for transparency.
• The UK Health Research Authority issued mandates to enforce trial result reporting.

These achievements mark a significant shift toward transparency becoming an expected, if not legally enforceable, norm. Tools like the FDAAA Trials Tracker help monitor sponsor compliance in real time.

Public Engagement and the Power of the Petition

One of the campaign’s most compelling tools was the public petition, which gathered over 90,000 signatures in its early years. This grassroots momentum added pressure on pharmaceutical companies and research institutions to commit publicly to transparency.

Major players like GSK and Johnson & Johnson acknowledged the movement, with GSK stating its commitment to post all results on its public register. Such corporate statements were seen as milestones in voluntary disclosure adoption by industry giants.

Integration with Broader Movements and Academic Research

AllTrials is closely aligned with the broader Open Science movement, which advocates for data sharing, reproducibility, and equitable access to research outputs. In academia, journals increasingly require trial registration as a precondition for publishing results, following guidelines by ICMJE and CONSORT.

Independent academic assessments have also validated the campaign’s impact. A 2020 study in PLOS Medicine showed significant improvements in results disclosure rates among large academic sponsors post-AllTrials. However, smaller institutions and investigator-initiated studies still lag behind.

Challenges: Enforcement, Monitoring, and Legacy Data

Despite the momentum, several challenges persist:

• Lack of enforcement for retrospective trials—especially pre-2007 data
• Inconsistent registry use outside of high-income countries
• Resource constraints at investigator-initiated research sites
• Limited punitive mechanisms for non-compliance

Furthermore, while some regulators have built trial data portals, interoperability and public usability vary significantly. For instance, the EU CTR and ClinicalTrials.gov differ in how they present and access summary results. Organizations like ClinicalStudies.in now play a role in bridging knowledge and training gaps for research teams globally.

Conclusion and Future Directions

The AllTrials campaign succeeded in raising global awareness about hidden data in clinical research and catalyzed regulatory and ethical reform. However, its work is far from complete. Strengthening enforcement, addressing non-reporting in low-resource settings, and ensuring accessibility of legacy data remain high-priority issues.

Transparency isn’t just a compliance box—it is a foundational pillar of good science and public trust. Sponsors, CROs, academic institutions, and regulatory bodies must continue to collaborate, ensuring that the vision of AllTrials—All Trials Registered. All Results Reported.—becomes a reality for all clinical research stakeholders.

For a deeper dive into global registry tools, visit EMA’s registry platform or access training resources on protocol transparency at PharmaValidation.in.